Sutro Biopharma Shares Are Trading Higher After Oppenheimer Maintained Its Outperform Rating and $10 Price Target on the Stock. The Company Recently Reported 2023 Financial Results
在奥本海默维持其跑赢大盘的评级和10美元的目标股价之后,Sutro Biopharma的股价走高。该公司最近公布了2023年财务业绩
Sutro Biopharma Shares Are Trading Higher After Oppenheimer Maintained Its Outperform Rating and $10 Price Target on the Stock. The Company Recently Reported 2023 Financial Results
在奥本海默维持其跑赢大盘的评级和10美元的目标股价之后,Sutro Biopharma的股价走高。该公司最近公布了2023年财务业绩
使用浏览器的分享功能,分享给你的好友吧